The estimated Net Worth of Steve Pakola is at least $5.86 Million dollars as of 5 March 2024. Steve Pakola owns over 12,878 units of Regenxbio Inc stock worth over $1,526,090 and over the last 6 years he sold RGNX stock worth over $423,253. In addition, he makes $3,908,790 as Senior Vice President and Chief Medical Officer at Regenxbio Inc.
Sign up
Steve Pakola RGNX stock SEC Form 4 insiders trading
Steve has made over 4 trades of the Regenxbio Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 12,878 units of RGNX stock worth $286,536 on 5 March 2024.
The largest trade he's ever made was selling 17,237 units of Regenxbio Inc stock on 2 January 2024 worth over $299,751. On average, Steve trades about 3,485 units every 79 days since 2018. As of 5 March 2024 he still owns at least 120,070 units of Regenxbio Inc stock.
You can see the complete history of Steve Pakola stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Steve Pakola biography
Dr. Steve Pakola M.D. serves as Senior Vice President, Chief Medical Officer of the Company. Dr. Pakola joins REGENXBIO from Aerpio Pharmaceuticals, Inc., where he was Chief Medical Officer. He has held key leadership roles in preclinical and clinical development, regulatory affairs and medical affairs. While Dr. Pakola's therapeutic area experience encompasses multiple indications, his predominant focus has been the development of treatments for retinal disorders, including clinical development experience in diabetic retinopathy, diabetic macular edema and age-related macular degeneration (AMD). He was the lead inventor and program lead for the Jetrea ® (ocriplasmin) program, from inception in 2002 through the therapy'sUnited Statesand European regulatory submissions in 2012. Prior to Aerpio, Dr. Pakola served as Chief Medical Officer at Amakem NV and as Senior Vice President and Chief Medical Officer at ThromboGenics NV. Earlier in his career, Dr. Pakola served as Associate Director of Cardiovascular Clinical Research at Boehringer Ingelheim, where he was Global Medical Lead on the Lipid-Lowering Development Programme and theUSAMedical Lead for the Direct Thrombin Inhibitor Development Programme. Prior to that, Dr. Pakola served in senior-level clinical development positions at Quintiles Cardiovascular Therapeutics and at Organon. Dr. Pakola earned a B.A., summa cum laude, and an M.D. from theUniversity of Pennsylvania, where he was elected to the Alpha Omega Alpha Honor Medical Society.
What is the salary of Steve Pakola?
As the Senior Vice President and Chief Medical Officer of Regenxbio Inc, the total compensation of Steve Pakola at Regenxbio Inc is $3,908,790. There are 1 executives at Regenxbio Inc getting paid more, with Kenneth Mills having the highest compensation of $6,147,270.
How old is Steve Pakola?
Steve Pakola is 51, he's been the Senior Vice President and Chief Medical Officer of Regenxbio Inc since 2019. There are 14 older and 4 younger executives at Regenxbio Inc. The oldest executive at Regenxbio Inc is Allan Fox, 72, who is the Chairman of the Board.
What's Steve Pakola's mailing address?
Steve's mailing address filed with the SEC is C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Insiders trading at Regenxbio Inc
Over the last 9 years, insiders at Regenxbio Inc have traded over $44,148,392 worth of Regenxbio Inc stock and bought 175,000 units worth $3,850,000 . The most active insiders traders include Llc Fmr, Argeris N Karabelas, and Edgar Engleman. On average, Regenxbio Inc executives and independent directors trade stock every 15 days with the average trade being worth of $238,185. The most recent stock trade was executed by Argeris N Karabelas on 3 September 2024, trading 10,000 units of RGNX stock currently worth $37,600.
What does Regenxbio Inc do?
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
What does Regenxbio Inc's logo look like?
Complete history of Steve Pakola stock trades at Regenxbio Inc and Aerpio Pharmaceuticals Inc
Regenxbio Inc executives and stock owners
Regenxbio Inc executives and other stock owners filed with the SEC include:
-
Kenneth Mills,
President, Chief Executive Officer, Executive Director -
Steve Pakola,
Senior Vice President, Chief Medical Officer -
Vittal Vasista,
Chief Financial Officer, Senior Vice President -
Olivier Danos,
Senior Vice President, Chief Scientific Officer -
Curran Simpson,
Senior Vice President - Product Development, Chief Technology Officer -
Kenneth T. Mills,
Pres, CEO & Director -
Vittal K. Vasista,
Chief Financial Officer -
Dr. Olivier Danos Ph.D.,
Chief Scientific Officer -
Curran M. Simpson M.S.,
Chief Operations & Technology Officer -
Patrick J. Christmas II, J.D.,
Chief Legal Officer -
Patrick J. Christmas II,
Chief Legal Officer -
Dr. Stephen Pakola,
Chief Medical Officer -
Luke Beshar,
Independent Director -
David Stump,
Independent Director -
Daniel Abdun-Nabi,
Independent Director -
A. N. Karabelas,
Lead Independent Director -
Daniel Tasse,
Independent Director -
Alexandra Glucksmann,
Independent Director -
Allan Fox,
Chairman of the Board -
Dr. Laura A. Coruzzi J.D., Ph.D.,
Sr. VP of Intellectual Property -
Ram Palanki,
Sr. VP of Commercial Strategy & Operations -
Dr. Laura A. Coruzzi,
Sr. VP of Intellectual Property -
Shiva G. Fritsch,
Chief People Officer -
Andrew Yost,
VP of Corp. Devel. -
Tricia Truehart,
VP of Investor Relations & Corp. Communications -
Stephen Yoo,
Chief Medical Officer -
Llc Fmr,
10% owner -
Camille D Samuels,
Director -
Faraz Ali,
Chief Business Officer -
Edgar Engleman,
Director -
James E Deerfield Mgmt L.P....,
-
Donald J Jr Hayden,
-
Patrick J. Christmas,
Chief Legal Officer -
Jean Bennett,
-
George V Migausky,
-
Jennifer Zachary,